Navigator Medicines, Inc. raised $100M in a Series A funding round co-led by RA Capital Management and Forbion to advance their bispecific antibody NAV-240 for autoimmune diseases.
PRIVATEAug 27, 2024
Amount Raised
$100 Million
Round Type
Series A
Scotch PlainsBiotechnologyHealth CareTherapeutics
Investors
ForbionRa Capital Management
Description
Navigator Medicines, Inc. has successfully closed a $100 million Series A financing to further develop NAV-240, a bispecific antibody targeting OX40L and TNFα. The funding will accelerate the clinical development of this innovative therapeutic and enhance their broader pipeline of immune regulation biologics.
Company Information
Company
Navigator Medicines
Location
Scotch Plains, New Jersey, United States
About
Navigator Medicines is a biotech company leading the advancement of biologics for targeted immune regulation & restoration. Founded in 2024 as a subsidiary of Sera Medicines, the Company is committed to developing new therapies for patients living with complex, heterogeneous autoimmune diseases. NAV-240, their clinical-stage bispecific antibody, targets OX40L and TNFα to address critical inflammatory diseases. The company is focused on innovation that enhances patient care.
Fundz sees it the moment Navigator Medicines raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Scotch PlainsBiotechnologyHealth CareTherapeutics